IXICO plc (PHYOF)
USD 0.07
(-90.91%)
USD 0.07
(-90.91%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 472.02 Thousand USD | -18.03% |
| 2022 | 575.85 Thousand USD | -28.4% |
| 2021 | 804.27 Thousand USD | 192.08% |
| 2020 | 275.36 Thousand USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - GBP | 0.0% |
| 2017 | - GBP | 0.0% |
| 2016 | - GBP | 0.0% |
| 2015 | - GBP | 0.0% |
| 2014 | - GBP | -100.0% |
| 2013 | 1.85 Million GBP | 0.0% |
| 2012 | - GBP | 0.0% |
| 2011 | - GBP | 0.0% |
| 2010 | - GBP | 0.0% |
| 2009 | - GBP | 0.0% |
| 2008 | - GBP | 0.0% |
| 2007 | - GBP | 0.0% |
| 2006 | - GBP | -100.0% |
| 2005 | 1000.00 GBP | 0.0% |
| 2004 | - GBP | 0.0% |
| 2003 | - GBP | -100.0% |
| 2002 | 8000.00 GBP | -87.3% |
| 2001 | 63 Thousand GBP | -45.69% |
| 2000 | 116 Thousand GBP | -0.85% |
| 1999 | 117 Thousand GBP | -28.22% |
| 1998 | 163 Thousand GBP | -1.21% |
| 1997 | 165 Thousand GBP | 157.81% |
| 1996 | 64 Thousand GBP | 166.67% |
| 1995 | 24 Thousand GBP | -45.45% |
| 1994 | 44 Thousand GBP | -22.81% |
| 1993 | 57 Thousand GBP | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 265.16 Thousand GBP | -43.82% |
| 2024 Q2 | 407.72 Thousand USD | 0.0% |
| 2023 Q4 | 472.02 Thousand USD | 35.16% |
| 2023 Q1 | 388.04 Thousand GBP | -32.61% |
| 2023 Q3 | 349.23 Thousand GBP | -44.15% |
| 2023 Q2 | 625.28 Thousand USD | 61.14% |
| 2023 FY | 472.02 Thousand USD | -18.03% |
| 2022 Q1 | 634.23 Thousand GBP | -21.14% |
| 2022 Q2 | 715.74 Thousand GBP | 12.85% |
| 2022 Q3 | 479.6 Thousand GBP | -32.99% |
| 2022 FY | 575.85 Thousand USD | -28.4% |
| 2022 Q4 | 575.85 Thousand USD | 20.07% |
| 2021 Q3 | 717.91 Thousand GBP | -9.82% |
| 2021 Q1 | 749.4 Thousand GBP | 172.15% |
| 2021 FY | 804.27 Thousand USD | 192.08% |
| 2021 Q4 | 804.27 Thousand GBP | 12.03% |
| 2021 Q2 | 796.08 Thousand GBP | 6.23% |
| 2020 Q4 | 275.36 Thousand GBP | 393.86% |
| 2020 Q1 | - GBP | 0.0% |
| 2020 Q2 | - GBP | 0.0% |
| 2020 FY | 275.36 Thousand USD | 0.0% |
| 2020 Q3 | 55.75 Thousand GBP | 0.0% |
| 2019 Q2 | - GBP | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q3 | - GBP | 0.0% |
| 2019 Q1 | - GBP | 0.0% |
| 2019 Q4 | - GBP | 0.0% |
| 2018 Q2 | - GBP | 0.0% |
| 2018 FY | - GBP | 0.0% |
| 2018 Q4 | - GBP | 0.0% |
| 2018 Q3 | - GBP | 0.0% |
| 2018 Q1 | - GBP | 0.0% |
| 2017 FY | - GBP | 0.0% |
| 2017 Q4 | - GBP | 0.0% |
| 2017 Q3 | - GBP | 0.0% |
| 2017 Q2 | - GBP | 0.0% |
| 2017 Q1 | - GBP | 0.0% |
| 2016 Q3 | - GBP | 0.0% |
| 2016 FY | - GBP | 0.0% |
| 2016 Q2 | - GBP | 0.0% |
| 2016 Q1 | - GBP | 0.0% |
| 2016 Q4 | - GBP | 0.0% |
| 2015 Q2 | - GBP | 0.0% |
| 2015 FY | - GBP | 0.0% |
| 2015 Q3 | - GBP | 0.0% |
| 2015 Q1 | - GBP | 0.0% |
| 2015 Q4 | - GBP | 0.0% |
| 2014 FY | - GBP | -100.0% |
| 2014 Q1 | - GBP | 0.0% |
| 2014 Q4 | - GBP | 0.0% |
| 2014 Q2 | - GBP | 0.0% |
| 2013 FY | - GBP | 0.0% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 Q4 | - GBP | 0.0% |
| 2012 Q4 | - GBP | 0.0% |
| 2012 FY | - GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2011 FY | - GBP | 0.0% |
| 2011 Q2 | - GBP | 0.0% |
| 2011 Q4 | - GBP | 0.0% |
| 2010 Q2 | - GBP | 0.0% |
| 2010 FY | - GBP | 0.0% |
| 2010 Q4 | - GBP | 0.0% |
| 2009 Q4 | - GBP | 0.0% |
| 2009 Q2 | - GBP | 0.0% |
| 2009 FY | - GBP | 0.0% |
| 2008 Q4 | - GBP | 0.0% |
| 2008 FY | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2007 FY | - GBP | 0.0% |
| 2007 Q2 | - GBP | 0.0% |
| 2006 Q4 | - GBP | 0.0% |
| 2006 Q2 | - GBP | 0.0% |
| 2006 FY | - GBP | -100.0% |
| 2005 Q4 | 1000.00 GBP | 0.0% |
| 2005 FY | 1000.00 GBP | 0.0% |
| 2005 Q2 | - GBP | 0.0% |
| 2004 Q2 | - GBP | 0.0% |
| 2004 Q4 | - GBP | 0.0% |
| 2004 FY | - GBP | 0.0% |
| 2003 Q4 | - GBP | 0.0% |
| 2003 FY | - GBP | -100.0% |
| 2003 Q2 | - GBP | 0.0% |
| 2002 Q2 | - GBP | 0.0% |
| 2002 FY | 8000.00 GBP | -87.3% |
| 2002 Q4 | 8000.00 GBP | 0.0% |
| 2001 FY | 63 Thousand GBP | -45.69% |
| 2000 FY | 116 Thousand GBP | -0.85% |
| 1999 FY | 117 Thousand GBP | -28.22% |
| 1998 FY | 163 Thousand GBP | -1.21% |
| 1997 FY | 165 Thousand GBP | 157.81% |
| 1996 FY | 64 Thousand GBP | 166.67% |
| 1995 FY | 24 Thousand GBP | -45.45% |
| 1994 FY | 44 Thousand GBP | -22.81% |
| 1993 FY | 57 Thousand GBP | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.32 Million USD | 97.678% |
| Skye Bioscience, Inc. | 4.61 Million USD | 89.773% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 98.414% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -285.325% |
| Qrons Inc. | 351.84 Thousand USD | -34.156% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 91.96% |
| BioStem Technologies, Inc. | 4.71 Million USD | 89.981% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 37.58% |
| CSL Limited | 12.18 Billion USD | 99.996% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 98.964% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 98.912% |
| Rebus Holdings, Inc. | 310 Thousand USD | -52.265% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 25.085% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -1735.309% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 98.854% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 88.549% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -17.463% |
| SQZ Biotechnologies Company | 27.47 Million USD | 98.282% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 79.706% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 50.223% |
| Mesoblast Limited | 118.7 Million USD | 99.602% |
| Marizyme, Inc. | 18.71 Million USD | 97.478% |
| Genus plc | 233.1 Million USD | 99.798% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 83.892% |
| Pharming Group N.V. | 171.54 Million USD | 99.725% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 46.848% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 64.868% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 37.064% |
| ContraFect Corporation | 2.88 Million USD | 83.616% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -248.39% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 67.364% |
| IMV Inc. | 28.88 Million USD | 98.366% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 91.658% |
| MultiCell Technologies, Inc. | 202.58 USD | -232905.726% |
| ONE Bio Corp. | 19.71 Million USD | 97.606% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.179% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 68.421% |
| Q BioMed Inc. | 4.1 Million USD | 88.515% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 98.574% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 61.573% |
| Biomind Labs Inc. | 735.54 Thousand USD | 35.827% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.302% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 84.402% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 96.368% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -31.223% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -233.543% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 79.099% |
| GB Sciences, Inc. | 1.75 Million USD | 73.17% |
| Alpha Cognition Inc. | 1.22 Million USD | 61.321% |
| HST Global, Inc. | 98.31 Thousand USD | -380.093% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -89.781% |
| Halberd Corporation | 150 Thousand USD | -214.682% |
| Enzolytics Inc. | 996.33 Thousand USD | 52.624% |
| Agentix Corp. | 50 Thousand USD | -844.046% |
| Resverlogix Corp. | 6.49 Million USD | 92.728% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -84.678% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 97.64% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 93.326% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 82.574% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -4516.362% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.887% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -135.287% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 80.314% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -105.862% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -217.531% |
| Kadimastem Ltd | 891.22 Thousand USD | 47.037% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -88.672% |
| LadRx Corporation | 33.6 Thousand USD | -1304.58% |
| Cell Source, Inc. | 9.25 Million USD | 94.899% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 37.58% |
| NovAccess Global Inc. | 2.19 Million USD | 78.543% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -106.686% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -123.734% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 90.527% |
| Mobile Lads Corp. | 484.28 Thousand USD | 2.532% |
| CytoDyn Inc. | 30.07 Million USD | 98.431% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 93.964% |
| SYBLEU INC | 477.5 Thousand USD | 1.147% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 90.032% |
| International Stem Cell Corporation | 4.17 Million USD | 88.702% |
| Bioxytran, Inc. | 1.92 Million USD | 75.479% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -656.29% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 78.357% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 94.324% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 94.502% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 69.654% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -76.128% |
| Neutra Corp. | 54.15 Thousand USD | -771.599% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 74.206% |
| PureTech Health plc | 25.51 Million USD | 98.15% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 61.443% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 96.955% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.242% |
| CSL Limited | 12.18 Billion USD | 99.996% |
| Cellectis S.A. | 92.77 Million USD | 99.491% |